Quick facts
- An influenza antigen detection test system is a named Class II entry in the United States at 21 CFR 866.3328.
- Influenza serological reagents sit in a different, lower entry: Class I at 21 CFR 866.3330.
- Canada has no named influenza entry: an influenza test is an in vitro diagnostic device and its class comes from Part 2 of the Medical Devices Regulations.
- A near-patient IVDD is Class III in Canada under Part 2 Rule 6 — and the Rule 9 table that lowers other devices does not name influenza.
- The default IVDD rule places any IVDD not reached by the other rules in Class I under Part 2 Rule 8.
- The regulation text cited here is current to 2026-09-21 and was last amended on 2026-06-17.
A rapid influenza test looks like a plastic cassette and reads like a strip. What it is, for a regulator, is a test used to detect an infectious agent — and the two countries do not weigh that the same way. One names the test and stops at Class II. The other asks where the test is used, and that single question lifts it a class.
What is a rapid influenza antigen test?
It detects influenza viral antigen in a respiratory specimen, and it exists to give a result while the patient is still in front of the clinician.
The test is run on a swab or an aspirate. A reagent in the device binds the antigen if it is present, and the result is read as a visible line or a signal. Because the whole run takes minutes, the test is used at the point of care — in a clinic room, a pharmacy or a bedside — rather than in a central laboratory that batches its work.
That distinction between where the test is run and what it detects is the whole of the difference between the two regulatory routes. One route is organised by the test; the other is organised by the setting.
How do Canada and the United States classify an influenza antigen test?
The test is Class II in the United States by name, and its Canadian class turns on where it is used.
| Item | Canada | United States |
|---|---|---|
| Influenza antigen detection test | Class III if near patient (Part 2 Rule 6) | Class II, 21 CFR 866.3328 |
| Influenza serological reagents | Class II or III by rule | Class I, 21 CFR 866.3330 |
| Influenza multiplex nucleic acid assay | Class III if near patient | Class II, 21 CFR 866.3980 |
| Default when no rule applies | Class I, Part 2 Rule 8 | Not applicable |
| Basis named in the rulebook | Rule and setting | Device entry and product code |
In the United States the antigen test is a named entry at 21 CFR 866.3328, and it is Class II. A multiplex nucleic acid assay is named at 21 CFR 866.3980, also Class II. The serological reagents — the antibody-based tests used differently — sit in the lower Class I entry at 21 CFR 866.3330. The entry, not the setting, drives the class.
In Canada there is no influenza entry at all. The test is an IVDD, and Part 2 Rule 6 states that a near-patient IVDD is classified as Class III. A test used at the point of care to detect an infectious agent falls inside that rule. The Rule 9 table, which reduces certain near-patient tests to Class II, names only pregnancy and fertility testing and cholesterol determination. Influenza is not in the table, so it stays where Rule 6 puts it.
Does the same rapid flu test sit in the same class in Canada and the United States?
No, and this is the point worth writing down: the same cassette is Class II in the United States and Class III in Canada when it is used near the patient.
| Scenario | Canadian class | US class |
|---|---|---|
| Antigen test used at the point of care | Class III, Part 2 Rule 6 | Class II, 21 CFR 866.3328 |
| Antigen test sent to a central laboratory | Lower class by rule | Class II, 21 CFR 866.3328 |
| Serological reagents in a reference laboratory | Class II or III by rule | Class I, 21 CFR 866.3330 |
The near-patient rule is what makes the Canadian class turn. In Canada the location where the result is produced is part of the classification, so a test designed for a clinic room is treated as the higher-risk configuration. In the United States the same setting does not change the entry.
For a laboratory or a clinic that runs the test, the practical consequence is narrow but real. It changes what the device file has to support and how the test is described in a submission. It does not change the specimen, the swab or the way the result is read on the bench.
Why does the near-patient rule matter more than the analyte?
Because a result delivered immediately can change a decision before a confirmatory result exists.
A central laboratory result arrives after the clinical decision has often been made. A near-patient result arrives while the patient is still there, which is exactly what makes point-of-care testing valuable and also what makes an erroneous result more consequential. The Canadian rules reflect that by lifting the near-patient configuration a class. The Rule 9 table carves out two narrow exceptions where the stakes are judged lower; everything else, including influenza, stays in the near-patient class.
This is a design choice about the setting, not a statement about the quality of any particular product. A test that is Class II in the United States is not thereby a lesser test. It is the same test, reaching its class through a different rule.
Which consumables does a point-of-care testing room restock?
A rapid test room runs on the collection and bench lines that surround the device. The sterile graduated 90 mL specimen cups carry samples to the bench, and the 120 mL sterile screw-cap container holds anything that has to be kept before it is processed. For the blood side of the same room, the sterilization monitoring collection pairs with the 24-hour monitoring five-pack trial where a clinic also runs its own sterilisation cycle. Clinics and multi-site groups ordering at case level use the wholesale ordering page, and the B2B wholesale collection lists the lines held for institutional buyers. Reselling? become a distributor.
What does a near-patient test require of the site?
Running a test at the point of care is a site decision as much as a device decision, and the rules reflect that.
A near-patient test has to be stored, run and read where the patient is. That means the site needs a controlled temperature for the kits, a bench that is not shared with specimen processing, a waste route for used swabs, and a record that ties the result to the operator. The test itself may be small, but the conditions around it are not, and those conditions are part of why the Canadian rules treat the near-patient configuration as the higher-risk one under Part 2 Rule 6.
The US side places the same conditions on the site through the entry rather than through a near-patient rule. An antigen test system filed at 21 CFR 866.3328 is Class II wherever it is used, and the site's obligations come from the test's instructions and from the laboratory framework, not from a class change.
For a clinic that is deciding whether to run a test at the point of care or send it out, the comparison is worth writing down. Point of care shortens the time to a result and adds a class in Canada. Send-out lengthens the time and keeps the collection device in its default class. Neither choice is wrong; they are different trade-offs, and the class is part of the trade-off.
Sources
- 21 CFR 866.3328, influenza virus antigen detection test system
- 21 CFR 866.3330, influenza virus serological reagents
- 21 CFR 866.3980, influenza multiplex nucleic acid assay
- 21 CFR 866.3332, novel influenza A detection
- 21 CFR 866.2900, microbiological specimen collection and transport device
- Medical Devices Regulations, SOR/98-282
- Public Health Ontario, laboratory services test index
- CLSI, clinical and laboratory standards
- CCOHS, OSH answers
- ISO 15189:2022, medical laboratories
- ISO 13485:2016, quality management
- ISO 14971:2019, risk management
- openFDA device classification API
- Opto, eye health library
- College of Optometrists of Ontario, standards of practice
- Canadian Paediatric Society, documents
- Canadian Dental Association
- Royal College of Dental Surgeons of Ontario
- ADA, science and research institute
- American Academy of Ophthalmology, eye health
A point-of-care result that is not recorded cannot be reconciled with a laboratory result later. The printable point-of-care testing log is a free sheet with columns for the patient, the test, the lot, the result and the operator, so a rapid result is written down rather than remembered. The point-of-care record generator on the same page sizes the sheet to the number of testing stations a site runs. No account and no sign-up are needed to open either one.
The class of a near-patient test depends on how your site runs it. Ask a compliance specialist and you will get a written answer specific to your equipment and province, with the regulation or standard it is based on cited.
Related reading
- Rapid Strep Tests in Canada vs the US: Which Rules Change?
- Nasopharyngeal Swabs in Canada vs the US: Which Collection Rules Apply?
- Blood Collection Tube Systems in Canada vs the US: Which Order Applies?
CliniEco Medical supplies laboratory, eye care and dental consumables of the kind described in this article. MDEL #35334. This article is written for laboratory, optometry and procurement professionals and is not legal advice; the class of a device and the records kept by a laboratory belong to the laboratory and to the requirements that apply to it.
Frequently Asked Questions
Is an influenza antigen test Class II in the United States?
Yes. An influenza virus antigen detection test system is Class II under 21 CFR 866.3328. Influenza serological reagents are a different and lower entry, Class I under 21 CFR 866.3330.
Why is the same test Class III in Canada?
Because Part 2 Rule 6 of the Medical Devices Regulations classifies a near-patient IVDD as Class III. A test used at the point of care to detect an infectious agent falls inside that rule.
Does the Rule 9 table lower an influenza test to Class II in Canada?
No. The Rule 9 table names only near-patient pregnancy and fertility testing and near-patient cholesterol determination. Influenza is not in the table, so it stays in the class Part 2 Rule 6 gives it.
Does where the test is run change the class in the United States?
No. In the United States the class comes from the named entry and the product code, not from the setting. In Canada the setting is part of the rule, and it is what turns the class.
What class does an IVDD take if no rule reaches it?
In Canada Part 2 Rule 8 places all other IVDDs in Class I. In the United States there is no equivalent default; the device is reached through a named entry.
What should a point-of-care testing record carry?
The patient, the test, the lot number, the result and the operator. The lot number is what lets a result be traced back to the reagents that produced it.
0 commentaire